Skip to content

The effect of ginger-quince compound on dyspepsia induced by chemotherapy and radiotherapy

Evaluating the effect of combined ginger and quince on dyspepsia in cancer patients undergoing concurrent chemotherapy and radiotherapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013111815436N1
Enrollment
40
Registered
2014-12-29
Start date
2013-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyspepsia. Somatoform autonomic dysfunction

Interventions

Intervention 1: Cases is prescribed standardized ginger and quince capsules three times a day, within 15 minutes of each meal, starting from 3 days before chemotherapy until completion of radiotherapy
Treatment - Drugs
Placebo
Cases is prescribed standardized ginger and quince capsules three times a day, within 15 minutes of each meal, starting from 3 days before chemotherapy until completion of radiotherapy period ( six we
Control group is prescribed placebo (lactose- bran compound) three times a day, within 15 minutes of each meal, starting from 3 days before chemotherapy until completion of radiotherapy period ( six w

Sponsors

Simorgh-e-Hekmat knowledge-base institute
Lead Sponsor
Research vice-chancellor, Tehran university of medical sciences and health services
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 139 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: suffering from cancer; definitely diagnosed by a pathologist; 18?? year-old or more; under chemotherapy treatments; simultaneous radiotherapy treatments inducing ?nausea and vomiting such as whole body or upper abdomen. Exclusion criteria: Warfarin and Heparin ?treatment; ASA consuming more than 80 mg; history of? blood disorders; history of severe thrombocytopenia; allergy to ginger or consuming it during the ?past week; gastro-intestinal cancers; having nausea and vomiting induced by factors except ?chemotherapy or radiotherapy such as CNS tumors, HTN, renal failure or hepatic disorders; gastrointestinal ?problems like gastric or peptic ulcers; forgetting the use of capsules three consecutive times or more.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Nausa. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Vomiting. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Bloating. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Anorexia. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Poor appetite. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Postprandial fullness. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdiyeh Falamarzi

Medicin college, Tehran university of medical sciences and health services

mhdy1227@gmail.com , m.falamarzi313@yahoo.com+98 21 6640 4377

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026